Dihexa, also known as N-hexanoic-Tyr-Ile-(6), is a peptide derived from angiotensin IV, known for its potent cognitive-enhancing effects. It works by binding to hepatocyte growth factor (HGF) receptors, promoting synaptogenesis (the formation of new synapses) and enhancing neural plasticity. Dihexa is primarily researched for its potential in treating neurodegenerative diseases like Alzheimer's disease and for cognitive enhancement in healthy individuals. Its ability to cross the blood-brain barrier and directly stimulate brain cell growth makes Dihexa a promising candidate for improving memory, learning, and overall cognitive function.

VIP (Vasoactive Intestinal Peptide) is a neuropeptide known for its vasodilatory, anti-inflammatory, and immune-modulating properties. It works by binding to specific receptors on cells, leading to the relaxation of smooth muscles, dilation of blood vessels, and suppression of pro-inflammatory cytokines. VIP is used in the treatment of conditions such as pulmonary arterial hypertension (PAH), inflammatory bowel disease (IBD), and autoimmune disorders. Its broad range of biological activities, including its ability to modulate immune responses and improve vascular function, makes VIP a versatile therapeutic agent in both inflammatory and vascular diseases.